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History of lung transplantation and introduction
Lung transplantation is a relatively young field. The first 
human lung transplant was performed in 1963 at the 
University of Mississippi (1). The recipient had emphysema 
and lung cancer obstructing the left mainstem bronchus 
and nephrotic syndrome. He underwent a left single lung 
transplant and was treated with mediastinal radiation, 
azathioprine, and steroids for immunosuppression. Post-
operatively, he was weaned from ventilatory support, but 
died 18 days later due to complications of renal failure. 
Post-mortem examination of the lung showed no evidence 
of rejection. In spite of the poor outcome, this case 
illustrated that a single transplanted lung would function, 
and that rejection could be averted at least for a brief time 
with the available immunosuppression at the time (1). 
Over the ensuing decade, 36 additional lung transplants 
were reported worldwide, but outcomes were uniformly 
poor (2). Many patients were moribund at the time of 
transplantation and would not be considered candidates 
today. Pneumonia, rejection, and respiratory failure were 
common causes of death, and there were no long-term 
survivors. Growing experience in heart and heart-lung 
transplantation paved the way for refinements in surgical 
techniques of lung transplantation. Additionally, the advent 
of cyclosporine and encouraging experience with its use 
in kidney transplantation facilitated the rebirth of lung 
transplantation (3,4). In 1983, the Toronto Lung Transplant 
Group performed the first successful lung transplant, and 
the results were reported as part of a two-patient series in 
1986 (5). This was the beginning of lung transplantation 
in the modern era, and volumes rapidly increased as lung 
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transplantation emerged as the ultimate treatment for end-
stage lung disease. In the latest International Society for 
Heart and Lung Transplantation (ISHLT) Registry report, 
over 4,600 lung transplants were performed in adults and 
children in 2016 (6). The indications span the spectrum 
of lung disease; interstitial lung disease (ILD), chronic 
obstructive pulmonary disease (COPD), and cystic fibrosis 
(CF) comprise approximately 80% of underlying diagnoses 
leading to transplant (6). Over the past 15 years, the volume 
of bilateral transplants has increased, and in 2016, 80% of 
all lung transplants reported to the ISHLT Registry were 
bilateral (6). Indeed, bilateral transplantation is associated 
with better long-term survival (6). 
Lung transplantation improves survival and quality of 
life when timed appropriately (7-11). Furthermore, there 
has been a significant improvement in survival after lung 
transplantation over time, and the median survival in the 
most recent era between 2009 and 2016 is 6.5 years (6). 
However, survival after lung transplantation remains 
significantly worse than after kidney, heart, and liver 
transplantation (12-14). Early after lung transplantation, 
infection and allograft failure due to primary graft 
dysfunction (PGD) are the leading causes of death; 
however, chronic rejection, termed chronic lung allograft 
dysfunction (CLAD), is the primary cause of death 
beyond the first year after transplantation, accounting for 
approximately 40–50% of deaths (6). Infection remains 
a significant problem at all time points, and according to 
the ISHLT Registry, 15–20% of deaths beyond the first 
year are due to infection (6). Thus, chronic rejection and 
infection account for up to 70% of deaths beyond the first 
year after lung transplantation. This underscores the critical 
role of the immune system and the delicate balance of 
appropriate immunosuppression after lung transplantation. 
More intensive immunosuppression may increase the 
risk and severity of infection and malignancy while less 
intensive immunosuppression increases the risk of rejection. 
Indeed, the inability to accurately gauge the degree of 
immunosuppression has been a significant challenge in 
clinical practice as the current approach of targeting various 
calcineurin inhibitor (CNI) trough levels or steroid or cell-
cycle inhibitor dose is grossly imprecise. 
Rejection after lung transplantation
Hyperacute rejection
Different forms of lung rejection exist, and an overview of 
these is presented here. Hyperacute rejection is a fulminant 
form of lung rejection that occurs within minutes or hours 
of reperfusion of the allograft (15-18). In clinical practice, 
distinguishing hyperacute rejection from severe PGD can 
be difficult, and the results of histocompatibility testing are 
critical to establishing the diagnosis. Pre-formed donor-
specific antibodies (DSA) cause hyperacute rejection. 
DSA are most commonly directed at mismatched human 
leukocyte antigens (HLA) although non-HLA antibodies 
may also cause hyperacute rejection (19). The paradigm 
for the pathogenesis of hyperacute rejection is that DSA 
bind HLA molecules on endothelial cells and activate 
the complement cascade which results in endothelial cell 
necrosis, exposure of the basement membrane, activation of 
the coagulation cascade and hemorrhagic infarction. Over 
the past 10 years, hyperacute rejection has become rare 
because of advances in HLA antibody detection methods. 
Indeed, solid phase assays have significantly improved the 
sensitivity and specificity of HLA antibody detection before 
transplantation (20,21). This allows transplant centers to 
identify unacceptable antigens for a sensitized patient on 
the waiting list and minimizes the possibility of a positive 
crossmatch and hyperacute rejection by avoiding the 
reactive HLA in a potential donor. Nevertheless, although 
hyperacute rejection has become quite rare, it demonstrates 
that antibodies can cause fulminant allograft rejection and 
that the capillary endothelium is the focal point of injury.
Acute cellular rejection (ACR)
In contrast, ACR is a common complication after lung 
transplantation. In the ISHLT Registry, approximately 
30% of adult lung transplant recipients experience at least 
1 episode of ACR in the first year after transplantation (6). 
However, large international registries may underestimate 
the incidence of ACR because of reporting limitations. 
In fact, some randomized controlled trials comparing 
the efficacy of different immunosuppressive agents have 
reported an incidence of ACR that ranges between 40–
50% (22,23). The highest incidence of ACR is in the first 
6 months after transplantation. Non-invasive approaches 
to the diagnosis of ACR including imaging studies and 
pulmonary function tests are insensitive and typically non-
specific. Consequently, transbronchial lung biopsy remains 
the gold standard for the diagnosis of ACR although the 
procedure is invasive and carries some risk of complications. 
According to the standard ISHLT definition of ACR, 
the characteristic histologic finding is the presence of a 
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mononuclear cell infiltrate circumferentially surrounding 
small vessels (24-26). The severity of ACR is based on the 
intensity of infiltration and extension into the adjacent 
interstitium. Minimal ACR (grade A1) is characterized 
by scattered perivascular infiltrates that are not easily 
visible at low magnification. The perivascular infiltrates 
are identifiable at low magnification in mild ACR (grade 
A2), and the infiltrate comprises activated lymphocytes, 
macrophages, and eosinophils that expand the vascular 
adventitia (Figure 1). Extension of the mononuclear cell 
infiltrate into the adjacent interstitium and frequent, 
obvious infiltrates at low magnification are characteristics 
of moderate ACR (grade A3). Severe ACR (grade A4) is 
very rare, and is characterized by diffuse infiltrates with 
necrotizing vasculitis and diffuse alveolar damage. 
Lower grades of ACR (e.g., A1 and A2) are typically 
clinically silent, and some cases of moderate ACR (grade 
A3) are asymptomatic. As a result, many transplant centers 
employ a surveillance bronchoscopy and transbronchial 
lung biopsy protocol to identify cases of ACR (27,28). 
There is no consensus on the utility of surveillance biopsies, 
and many centers advocate biopsies only if patients develop 
signs or symptoms of allograft dysfunction (29). Proponents 
of a surveillance protocol argue that early treatment of ACR 
may decrease the likelihood of higher grades of ACR or the 
development of CLAD although empirical evidence to support 
this is lacking. Nevertheless, historical data suggest that 
programs that do not use a surveillance protocol may perform 
an equivalent number of procedures because the threshold to 
pursue a clinically indicated biopsy may be lower (30). 
There is little data about the natural history of ACR. In 
an early study, asymptomatic patients with mild ACR (grade 
A2) who were not treated were followed clinically (31). 
Ten of 16 patients worsened: 4 had persistent A2 rejection, 
4 progressed to A3 rejection, 1 developed obliterative 
bronchiolitis (OB), and 1 developed severe lymphocytic 
bronchiolitis (31). In addition, 5 of these 10 developed 
bronchiolitis obliterans syndrome (BOS) during the study 
follow-up (31). As a result, most patients with mild ACR 
(grade A2) are treated with bolus methylprednisolone. 
Furthermore, multiple studies have identified a significant 
association between ACR and the subsequent development 
of BOS (32-35). Indeed, even episodes of minimal ACR 
(grade A1) are associated with an increased risk of BOS 
(33-35). Nevertheless, although these studies have identified 
an association between ACR and BOS, this should not 
suggest that ACR causes BOS. Indeed, it is unclear how the 
perivascular inflammation characteristic of ACR would result 
in small airway fibrosis. It is possible that ACR is a marker of 
the underlying alloimmune response that causes BOS. 
Lymphocytic bronchiolitis
Lymphocytic bronchiolitis is characterized by peribronchiolar 
mononuclear cell infiltrates (26). This airway inflammation 
often accompanies higher grades of ACR and is considered 
airway directed acute rejection if there are no signs of a 
superimposed infection. The ISHLT working formulation 
for lung allograft rejection defines lymphocytic bronchiolitis 
grade B1R as submucosal peribronchiolar mononuclear 
cell infiltrates without epithelial damage or intra-epithelial 
lymphocytic infiltration (26). Grade B2R is defined as 
more intense inflammation with activated mononuclear 
cells including eosinophils and there is intra-epithelial 
infiltration and epithelial ulceration or necrosis (26). 
Previous studies have noted that lymphocytic bronchiolitis 
can be refractory to steroid therapy and is associated with 
an increased risk of BOS development and death (36,37). 
The evolution of epithelial ulceration and necrosis to 
fibrosis and luminal obliteration characteristic of OB is a 
reasonable explanation for this association. With this in 
mind, undiagnosed concomitant lymphocytic bronchiolitis 
may be the explanation for the association between ACR 
and BOS.
Antibody-mediated rejection (AMR)
AMR is an increasingly recognized form of lung allograft 
rejection. In recent years, multiple case reports and case 
series from different centers describing the presentation and 
Figure 1 This transbronchial lung biopsy illustrates a case of 
mild acute cellular rejection (grade A2). A mononuclear cell 
infiltrate that expands the vascular adventitia is easily visible at low 
magnification. Hematoxylin and eosin staining, ×40.
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clinical features of AMR have been published (38-45). Based 
on these findings and experience in kidney transplantation, 
the ISHLT developed a consensus definition for pulmonary 
AMR (46). According to this definition, the diagnosis of 
definite AMR is made if all of the following criteria are present:
 Clinical allograft dysfunction;
 Lung injury pathology;
 Capillary C4d deposition;
 Circulating DSA;
 Clinical exclusion of other possible causes of allograft 
dysfunction.
The diagnostic certainty is dependent on the number of 
criteria present. If one of the above criteria is absent, the 
diagnosis of AMR is considered probable, and if 2 of the above 
criteria are absent, the diagnosis is considered possible (46). 
However, because C4d staining and interpretation have 
been problematic in lung transplantation, the committee 
noted that a diagnosis of AMR can be confidently made in 
the absence of C4d deposition if all other criteria are present. 
This ISHLT definition for pulmonary AMR will 
facilitate future research and standardize the diagnosis 
across centers. However, the definition is complex and relies 
on a multi-disciplinary approach. Indeed, the diagnosis 
of AMR remains a difficult one and requires a high index 
of suspicion. It is important to note that the histologic 
features are typically non-specific. These may include acute 
and organizing lung injury, pneumonitis, diffuse alveolar 
damage, capillaritis, and ACR. In the right clinical setting, 
neutrophilic capillaritis raises the suspicion for AMR (47,48). 
The characteristic findings are neutrophilic infiltration with 
karyorrhectic debris in alveolar septa (Figure 2). However, 
neutrophilic capillaritis is not a sensitive finding. Although 
C4d deposition provides direct immunopathologic evidence 
of the effect of antibodies, many cases that have all other 
criteria are C4d-negative (43,45,48). Indeed, a recent 
relatively large single center study compared the clinical 
presentation, DSA characteristics, histologic findings, and 
outcomes of C4d-positive cases to C4d-negative cases of 
AMR (48). There were no significant differences between 
the two groups with the exception that C4d-negative cases 
were more likely to be due to non-complement binding 
DSA (48). The authors proposed that C4d-negative cases 
of AMR be considered definite AMR if all other criteria 
are present. In addition, they suggested that some C4d-
negative cases might be due to complement-independent 
pathways (48). Furthermore, C4d-negative AMR is now a 
widely recognized form of AMR in kidney transplantation 
(49,50). The diagnosis of AMR remains difficult because 
of the absence of specific histologic findings and the 
inconsistencies of C4d staining. Confounding matters 
further, DSA are common but do not necessarily lead to 
AMR, and there are various causes of allograft dysfunction. 
Clearly, better diagnostics are necessary to facilitate the 
identification of AMR. Finally, although AMR may be a 
reversible form of allograft failure, there is a high incidence 
of CLAD among survivors (42-45,48). 
Chronic lung allograft dysfunction
As noted above, CLAD is the leading cause of death 
beyond the first year after lung transplantation (6). CLAD 
is stratified into two phenotypes with potential overlap 
between these. BOS is the prototypic form of CLAD and 
was recognized in the late 1980s as the critical barrier 
to better long-term outcomes after heart-lung and lung 
transplantation (51-54). OB, a fibroproliferative scarring 
of membranous and respiratory bronchioles that results 
in luminal obliteration, is the characteristic histology of 
BOS (Figure 3). However, the sensitivity of transbronchial 
lung biopsy for the diagnosis of OB is poor because of the 
small sample size and the patchy nature of OB. As a result, 
BOS is the clinical surrogate for OB and is defined based 
on obstructive changes in spirometry with progressive 
stages defined according to the magnitude of decrease from 
baseline (53,54). Restrictive allograft syndrome (RAS) has 
been recognized over the past 10–15 years as a more rapidly 
progressive form of CLAD (55-58). There are significant 
differences in spirometry and imaging studies between 
RAS and BOS. BOS is characterized by an obstructive 
Figure 2  Neutrophilic capillaritis with neutrophils and 
karyorrhectic debris in the alveolar septa. Hematoxylin and eosin 
staining, ×400.
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ventilatory defect whereas RAS manifests with a restrictive 
ventilatory abnormality. A challenge to the diagnosis of 
RAS is that measuring total lung capacity (TLC) has not 
been a part of routine pulmonary function testing at most 
transplant centers. Thus, baseline values are not available 
for comparison at disease onset. The pathology of RAS has 
not been extensively studied. In one series of 16 patients 
with RAS who had available pathology specimens, 15 had 
pleuroparenchymal fibroelastosis and 1 had diffuse alveolar 
damage (59). It is noteworthy that 14 of the 16 patients had 
concomitant OB (59). This raises questions about whether 
RAS is truly a distinct and unique phenotype of CLAD 
or whether it represents a more advanced or severe form. 
Furthermore, in the original descriptions of OB as chronic 
lung allograft rejection after heart-lung transplantation, 
diffuse interstitial and pleural fibrosis as well as a concomitant 
restrictive ventilatory abnormality were noted (60,61). 
Patients with BOS typically have no abnormalities on 
chest X-ray or chest computed tomography (CT) until 
advanced stages where mosaic attenuation, bronchial 
dilation, or air trapping may appear (62). In contrast, upper 
lobe predominant coarse radiographic opacities on chest 
X-ray and CT scan are characteristic of RAS (55,57,58). 
Figure 4 illustrates differences in spirometry and CT scan 
findings between a patient with advanced BOS (Figure 4A) 
and a patient with advanced RAS (Figure 4B). A clinical 
presentation with features of both BOS and RAS is 
possible. In addition, some patients may present with 
BOS at the onset of CLAD diagnosis and evolve into 
RAS and vice versa (57). Figure 5 illustrates an example 
of a patient who progressed from BOS to RAS over time. 
The patient developed BOS 18 months after bilateral lung 
transplantation (Figure 5A). In spite of intensive treatment, 
CLAD progressed and by 54 months after transplantation, 
he had advanced RAS (Figure 5B). At autopsy, the patient 
was noted to have extensive OB, interstitial fibrosis, and 
mild ACR. 
Evidence-based treatment options for CLAD are 
limited. There has been only one randomized controlled 
trial for the management of CLAD where 48 patients with 
BOS were randomized to azithromycin or placebo (63). In 
this study, five patients who were randomized to placebo 
crossed over to open label azithromycin, and there was 
no significant difference between the azithromycin and 
the placebo group in the intention to treat analysis (63). 
However, among those who completed the study, azithromycin 
was associated with improved lung function compared 
to placebo (63). Beyond azithromycin, treatment options 
include bolus methylprednisolone, anti-thymocyte globulin, 
alemtuzumab, and extracorporeal photopheresis (64-69). 
In spite of aggressive treatment, the clinical course is 
typically progressive resulting in respiratory failure and 
death or re-transplantation in the majority of patients. The 
median survival after the diagnosis of BOS is approximately 
2.5 years (70). However, survival after the diagnosis of RAS 
is significantly worse (57). Clearly, improved prevention 
and treatment of CLAD are necessary to improve patient 
outcomes after lung transplantation. 
Infection
Lung transplant recipients are at increased risk of infection 
at all time points, and infection is a common cause of death 
accounting for up to 20% of all deaths beyond the first year 
after transplantation (6). Therapeutic immunosuppression 
is necessary to mitigate the risk of rejection, but this 
inherently increases the risk of infection. Furthermore, 
local host defenses are impaired with the loss of lymphatic 
drainage and impaired mucociliary clearance and cough 
mechanism after lung transplantation. Lastly, the lung 
allograft is in constant contact with the environment, 
and this increases the risk of acquiring infections. In the 
immediate period after transplantation, donor-transmitted, 
recipient-derived, and nosocomial infections are most 
common. Typical donor-transmitted infections are bacterial 
pneumonia and community-acquired respiratory viral 
(CARV) infections. Mycobacterial and endemic fungal 
infections are less common, and systemic viral infections 
(e.g., human immunodeficiency virus, hepatitis C virus) 
are exceedingly rare with current donor testing protocols. 
Common nosocomial infections include bacterial pneumonia, 
surgical site infection, empyema, and Clostridium difficile 
colitis. In general, patients are treated with empiric broad-
Figure 3 Obliterative bronchiolitis with mural fibrosis and smooth 
muscle hypertrophy. Hematoxylin and eosin staining, ×40.
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Figure 4 Spirometry and chest computed tomography (CT) scan. (A) Spirometry and chest CT scan from a patient with advanced 
bronchiolitis obliterans syndrome (BOS) are illustrated. There is a severe obstructive ventilatory defect and a clear chest CT. (B) Spirometry 
and CT scan from a patient with advanced restrictive allograft syndrome (RAS) are illustrated. Spirometry shows reduction in forced vital 
capacity (FVC) and forced expiratory volume in 1 second (FEV1) in a pattern suggestive of a restrictive ventilatory abnormality. CT scan 
illustrates coarse fibrotic interstitial opacities. 
spectrum antibacterial antibiotics for the first 7–14 days after 
transplantation, and the choice of agents is adjusted based on 
donor and recipient culture results. 
The risk of opportunistic infections is highest in the first 
6 months after transplantation. The risk of cytomegalovirus 
(CMV) infection depends on the serologic status of the 
donor and the recipient, and seronegative recipients of 
organs from seropositive donors have the highest risk. 
Transplant programs use different prophylactic regimens 
to prevent CMV infection. In a multicenter randomized 
controlled trial, extended prophylaxis with valganciclovir 
to 12 months after transplantation was associated with 
a significantly lower incidence of CMV disease, CMV 
infection, and disease severity compared to 3 months of 
prophylaxis (71). Other prophylactic regimens have not 
been as carefully studied, but most patients are treated with 
an antibiotic for prophylaxis against Pneumocystis jiroveci 
pneumonia. Recipient-derived infections remain common 
in the first 6 months. In addition, community-acquired 
infections including CARV (e.g., influenza, respiratory 
syncytial virus, etc.), bacterial pneumonia and endemic 
fungi (e.g., histoplasmosis, coccidioidomycosis) can be a 
significant cause of morbidity.
Infections can have an immediate and direct impact 
on lung transplant recipients resulting in hospitalization 
and increased health care utilization (72). Furthermore, 
multiple infections have been associated with an increased 
risk of CLAD development and progression in the ensuing 
months after the infection (72-74). Respiratory viral 
infections have been linked to the development of BOS (73). 
The development of epithelial fibrosis and luminal 
obliteration characteristic of OB after viral bronchiolitis is 
easy to envision. In addition, bacterial respiratory infections 
including Staphylococcus aureus and Pseudomonas aeruginosa 
and fungal colonization with Aspergillus species have been 
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relationship between the isolation of Pseudomonas aeruginosa 
and CLAD is more complex. In a large single center study, 
de novo acquisition of Pseudomonas aeruginosa was associated 
with an increased risk of CLAD, but the persistence of pre-
transplant Pseudomonas aeruginosa culture positivity post-
transplant was not (79). A paradigm for the association 
between infections and the development of CLAD is that 
organisms stimulate the release of chemokines from the 
allograft resulting in the recruitment of leukocytes which 
further amplify the recruitment of additional inflammatory 
cells and allograft injury (80). It is also possible that 
alloimmune responses injure the airway epithelium first, 
and this increases the risk of infection. 
Conclusions
Lung transplantation is the ultimate treatment for 
patients with advanced lung disease. Although there have 
been significant improvements in survival since lung 
transplantation became a clinically viable treatment in the 
1980s, survival after lung transplantation continues to lag 
behind survival after other solid organ transplants. Indeed, 
long-term outcomes remain disappointing in spite of 
advances in donor and recipient selection and management. 
Rejection and infection are the leading causes of death 
after transplantation. This highlights the critical role of 
the immune response after transplant and underscores the 
need for better clinical immunosuppression and immune 
monitoring. Clearly, there are ongoing unmet needs in 
the management of lung transplant recipients, and future 
studies are necessary to continue to advance the field and 
improve patient outcomes. 
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